American BioMed Launches Distributor Alliance and Renews Shareholder Communications Through DeMonte Associates.Business Editors THE WOODLANDS, Texas--(BUSINESS WIRE)--March 29, 2000 American BioMed, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ABMI ABMI Autologous Bone Marrow Infusion ) today reported that it has initiated a distributor alliance with and received opening orders from the Pharmed Group of Miami, Florida. The Pharmed alliance facilitates opening of a distribution channel for sales of the Company's silicone catheter products in Latin America and the Caribbean. Pharmed's Vice President for International Sales, Alex Lazaro, added, "We are very excited to be able to offer our distributor network the quality products from American BioMed. Over the next few months, we will undertake product registration in the countries with these requirements, so that full-scale promotion can proceed as soon as possible." Marshall Kerr, the Company's President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. commented, "This agreement overcomes a previous gap in our distributor network, easing our entry into a valued new geographic market. We believe this is a favorable milestone on our path from a developmental to an operating entity." In further news, the Company announced that it has resumed its relationship with DeMonte Associates. DeMonte Associates is a professional investor relations Investor relations The process by which the corporation communicates with its investors. firm which specializes in shareholder communications on behalf of high-growth biotechnology companies. American BioMed, Inc. develops, manufactures and markets devices for minimally-invasive interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based and other surgical procedures. This release contains forward-looking statements made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. While based on assumptions the Company believes are reasonable, actual results could differ materially based on changes in these or unforeseen factors, and the Company assumes no obligation to publicly update or revise any forward-looking statements herein. Among such uncertainties are government regulation; results of research, development, and clinical testing; general economic and other market conditions; pricing and reimbursement for medical care; and market competition. Please see the Company's Securities and Exchange Commission filings for detailed discussion of such risk factors. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion